Analyst Research

Report Title Price
Provider: S&P Capital IQ Factual Report
$138.00
Provider: Pechala's Reports
$15.00
Provider: Reuters Investment Profile
$20.00
Provider: Thomson Reuters Stock Report
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

CryoLife Inc Issues FY 2013 Guidance; EPS Guidance Below Analysts' Estimates


Thursday, 14 Feb 2013 08:02am EST 

CryoLife Inc announced that for fiscal 2013, it expects total revenues to be between $139.0 million and $143.0 million and earnings per share (EPS) of between $0.25 and $0.28 in 2013, which includes the increased research and development expenses described above and the anticipated impact of the U.S. medical device excise tax implemented in 2013 as part of the Affordable Care Act. According to I/B/E/S Estimates, analysts on an average were expecting the Company to report revenue of $142.4 million and EPS of $0.31 for fiscal 2013. 

Company Quote

9.89
0.08 +0.82%
17 Apr 2014